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 ABSTRACT
Secondary hyperparathyroidism is a common 
complication of chronic kidney disease. The elevated 
serum intact parathyroid hormone, phosphorus, 
calcium and calcium x phosphorus product have been 
independently associated with an increased relative 
risk of mortality. The standard therapy for secondary 
hyperparathyroidism, including active vitamin D 
analogues and phosphate binders, is often insuffi-
cient to allow patients to achieve the recommended 
Kidney Disease Outcomes Quality Initiative targets 
for bone and mineral metabolism. Randomised con-
trolled phase III clinical studies in chronic kidney 
disease patients with secondary hyperparathyroidism 
have shown that cinacalcet treatment increases the 
proportion of patients achieving the recommended 
Kidney Disease Outcomes Quality Initiative targets 
for intact parathyroid hormone, phosphorus, calcium 
and calcium x phosphorus product.
Aims: This observational multicentre study aims 
to evaluate cinacalcet’s ability to achieve and main-
tain Kidney Disease Outcomes Quality Initiative 
targets in a population with secondary hyperpara-
thyroidism on chronic haemodialysis in Portugal.
Patients and Methods: Patients on chronic dialy-
sis that received cinacalcet during a free sampling 
programme were enrolled. Retrospective and pro-
spective monthly data were collected from 3 months 
before until 6 months after the beginning of cina-
calcet treatment. Additional assessment included a 
12 month evaluation of all parameters.
Results: 140 dialysis patients with secondary 
hyperparathyroidism were enrolled, 60% male, mean 
age 57.4±14.1 years. The mean intact parathyroid 
hormone, calcium, phosphorus, and calcium x phos-
phorus product values at baseline were 751.7±498.8 
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pg/ml, 9.7±3.8 mg/dl, 5.5±1.5 mg/dl, and 52.7±25.3 
mg2/dl2, respectively.
After 6 months’ cinacalcet treatment, 26.2%, 
53.6%, 59.3%, and 81.0% of the patients achieved 
the Kidney Disease Outcomes Quality Initiative rec-
ommended levels for intact parathyroid hormone, 
calcium, phosphorus, and calcium x phosphorus 
product, respectively. The mean dose of cinacalcet 
at 6 months was 57.1±29.7 mg/day.
Conclusions: The use of cinacalcet in clinical 
practice is an effective option for the treatment of 
secondary hyperparathyroidism in chronic dialysis 
patients, allowing more patients to reach and main-
tain the Kidney Disease Outcomes Quality Initiative 
targets.
Key-Words:
Biochemical parameters; calcimimetics; cinacalcet; 
dialysis; Kidney Disease Outcomes Quality Initiative 
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 INTRODUCTION
Secondary hyperparathyroidism (SHPT) is common 
in chronic kidney disease (CKD) patients receiving 
haemodialysis1. According to previous studies and 
the Dialysis Outcomes and Practice Patterns Study 
(DOPPS), the estimated proportion of haemodialysis 
patients with SHPT, defined by intact parathyroid 
hormone (iPTH) levels higher than 300 pg/mL, 
ranges from 30 -50%2,3. A majority of untreated CKD 
patients will develop SHPT as a result of the kidney’s 
inability to maintain mineral homeostasis. SHPT is 
characterised by persistently elevated levels of para-
thyroid hormone (PTH) and progressive parathyroid 
gland hyperplasia. Parathyroid glands are respon-
sible for maintaining calcium homeostasis through 
PTH action. PTH increases the release of calcium 
from bone and stimulates the synthesis of calcitriol, 
increasing calcium absorption from the gastrointes-
tinal tract4.
The elevated serum PTH, phosphorus (P), calcium 
(Ca) and calcium x phosphorus product (CaxP) asso-
ciated with SHPT has been independently associ-
ated with an increase relative risk of mortality. The 
standard therapy for SHPT, including active vitamin 
D analogues and phosphate binders, is often insuf-
ficient to allow patients to achieve the recom-
mended Kidney Disease Outcomes Quality Initiative 
(K/DOQI) targets for bone and mineral metabolism5. 
Randomised controlled phase III clinical studies in 
CKD individuals with SHPT, have shown that the use 
of the calcimimetic agent, cinacalcet, increases the 
proportion of patients achieving the recommended 
K/DOQI targets for iPTH, P, Ca and CaxP6 -9. This 
situation usually becomes more severe as kidney 
function declines. Also, these alterations in bone 
and mineral metabolism have been associated with 
vascular calcification, cardiovascular disease and 
increased mortality risk10-16.
The interaction between these factors is complex, 
and effective control of SHPT is often difficult to 
achieve8,9,11,17.
Various treatment strategies are currently recom-
mended to correct mineral metabolism and bone 
disease in patients with CKD17. Standard therapy for 
SHPT includes optimisation of dialysis, calcium 
supplementation, dietary phosphorus restriction, use 
of phosphate binders, and treatment with vitamin D 
sterols2,17. Until the availability of calcimimetics, 
surgical parathyroidectomy was usually the unique 
alternative to control severe SHTP.
Vitamin D sterols treatment has major direct or 
indirect effects on serum levels of PTH, calcium and 
phosphorus, and its use is frequently limited by the 
hypercalcaemia and hyperphosphataemia associated 
with this therapy17,18. The K/DOQI guidelines high-
light the importance of controlling these levels, 
namely in dialysis patients with SHPT5.
Despite the use of new medications, a significant 
proportion of patients routinely receiving dialysis 
have high plasma PTH levels, marked hypercalcaemia 
and hyperphosphataemia2,17. Attempts have been 
made to develop pharmacological compounds able 
to control the iPTH secretion without increasing Ca 
and P levels in these patients7. Cinacalcet represents 
a possible alternative or adjuvant to vitamin D ste-
rols treatment6 -9. Cinacalcet increases the sensitiv-
ity of the calcium -sensing receptor to extracellular 
ionised calcium, inhibits the release of PTH, lowering 
its levels within a few hours of administration and 
reduces serum calcium and phosphorus levels. This 
mechanism of action differs fundamentally from that 
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of vitamin D sterols, which diminish the transcription 
of the PTH gene and hormone synthesis over a 
period of several hours or days.
This study’s main objective was to evaluate cina-
calcet’s ability in daily clinical practice to achieve 
and maintain K/DOQI targets (iPTH, Ca, P, and CaxP) 
in CKD stage 5 patients on chronic dialysis in Por-
tugal, over a period of 6 months after the start of 
treatment.
 PATIENTS AND METHODS
 Study design
An observational multicentre study was con-
ducted in 9 dialysis units in Portugal. CKD stage 5 
patients on chronic dialysis receiving cinacalcet at 
their nephrologist’s discretion were enrolled. Retro-
spective and prospective monthly data on patients’ 
demographics, laboratory parameters, cinacalcet 
dose and frequency and other concomitant medica-
tion were collected from 3 months before until 6 
months after cinacalcet treatment. Additional assess-
ment included a 12 months evaluation of all param-
eters.
No other clinical visits, laboratory or diagnostic 
tests, other than those regularly scheduled and 
associated with usual normal practice were required 
as part of this study.
 Study endpoints
The primary endpoint was the proportion of 
patients with iPTH>150 and <300 pg/ml, CaxP<55 mg2/
dl2, Ca≥8.4 and <9.5 mg/dl, and P<5.5 pg/ml, 6 
months after the beginning of cinacalcet treat-
ment.
Secondary endpoints included the proportion of 
patients who maintained K/DOQI recommended 
targets at the end of the 12 month study period, 
and the influence of baseline characteristics such as 
PTH, gender, age, time on dialysis on the response 
to cinacalcet treatment. The effect of cinacalcet treat-
ment on concomitant medications, namely Vitamin 
D and phosphate binders was also evaluated.
 Statistical analysis
The statistical analysis included the description 
of patients’ demographics and clinical characteristics 
considering absolute and relative frequencies for 
categorical variables, and mean±standard deviation 
(SD), and range for continuous variables.
Mean values for iPTH, Ca, P, and CaxP were cal-
culated. Primary endpoint, meaning the proportion 
of patients who achieved each K/DOQI recommend-
ed targets at 6 months, and 95% confidence inter-
vals was calculated. These analyses were also per-
formed for the 12 month evaluation in order to 
assess the secondary endpoints. McNemar’s test was 
used to compare the 6 and 12 month results.
The independent influence of age, gender and 
clinical variables on treatment efficacy was assessed 
using the chi -square test for age, and the indepen-
dent sample t-test for the others, for comparisons 
between patients who achieved K/DOQI recom-
mended targets and those who did not.
The over -time changes in iPTH, Ca, P, and CaxP 
values after cinacalcet treatment were calculated for 
all patients as an additional exploratory analysis.
All p-values were two -sided and those ≤0.05 were 
considered to indicate statistical significance. Statis-
tical analysis was performed using SPSS software 
version 15.0.
Last observation was carried forward for primary 
endpoint variables missing data.
 RESULTS
 Patients
A total of 140 patients, 60.0% male, mean age 
57.4±14.1 years were enrolled in the study. Fifteen 
percent were diabetic (19 patients), and 2.1% had 
undergone parathyroidectomy (3 patients). At enrol-
ment, 47.9% of the patients were receiving intravenous 
calcitriol (67 patients), 42.9% oral calcitriol (60 patients), 
55.7% calcium -containing phosphate binding agents 
(78 patients), and 81.4% sevelamer (114 patients). Mean 
previous time on dialysis was 4.7±4.3 years.
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Laboratory values before, at baseline, and after 
cinacalcet treatment are given in Table I.
The mean iPTH, Ca, P, and CaxP values at base-
line were 751.7±498.8 pg/ml, 9.7±3.8 mg/dl, 5.5±1.5 
mg/dl, and 52.7±25.3 mg2/dl2, respectively.
After cinacalcet, the decreases in iPTH, Ca, P, and 
CaxP values were statistically significant (p<0.001) 
until the 4th month, when comparing each month to 
the month immediately prior. After that the values 
did not change significantly.
After 6 months of cinacalcet treatment, 26.1%, 
53.6%, 59.3%, and 81.0% of the patients achieved 
the K/DOQI recommended levels for iPTH (150-300 
pg/ml), Ca (8.4 -9.5 mg/dl), P (3.5 -5.5 mg/ml), and 
CaxP (<55 mg2/dl2).
At 12 months, these percentages were 39.5%, 
47.0%, 65.0%, and 77.2%, respectively.
The differences between baseline, 6 and 12 month 
evaluations were statistically significant for iPTH 
(p<0.001), Ca (p<0.001), and CaxP (p=0.0184). No 
statistically significant differences were observed 
between P levels (p=0.320). Evolution of iPTH 
median values is presented in Figure 1.
Neither gender, age nor time on dialysis, had a 
significant influence on treatment response.
The group of patients that did not achieve K/DOQI 
iPTH targets had a statistically higher mean baseline 
iPTH value (749.6±410 vs. 557.8±223.1; p=0.018).
The mean cinacalcet dose at 6 months was sig-
nificantly higher for patients who did not achieve 
K/DOQI iPTH targets at 12 months (61.4±25.1 vs. 
48.4±23.6 mg/day; p=0.014).
At 6 and 12 months the percentage of patients 
with iPTH value inferior to 150 pg/mL was 13.9% and 
16.7%, respectively.
The mean daily doses of cinacalcet were 30 mg/
day at baseline and 57.1±29.7 and 62.6±26.5 mg/
day at 6 and 12 months of treatment, respectively. 
Mean variations in daily doses between periods were 
statistically significant (baseline vs. 6 months and 
baseline vs. 12 months; p<0.001).
 Concomitant medication
At baseline, mean intravenous and oral calcitriol 
doses were 3.6±1.6 and 2.0±1.4 μg/week, respectively., 
Mean baseline doses of calcium -containing phosphate 
binders and sevelamer were 2.6±1.6 g/day and 
4932.0±2169.3 mg/day, respectively. At the 12th month, 
mean intravenous (IV) and oral calcitriol doses were 
3.0±1.4 and 1.3±0.8 μg/week, respectively. The mean 
doses at the 12th month of calcium -containing phos-
phate binders and sevelamer were 3.7±2.2 g/day and 
4211.6±2148.6 mg/day respectively.
Neither the vitamin D sterols nor sevelamer aver-
age doses significantly changed throughout the 12 
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Table I
Evolution of the biochemical parameters evaluated during the study period
Laboratory values -3 months Baseline 6 months 12 months





















Evolution of the plasma iPTH median levels during the study. Median value 
(quartiles). The blue lines represent the recommended KDOQI range for iPTH.
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month treatment period. Mean dose of calcium-
-containing phosphate binder significantly increased 
during the study (baseline vs. 6 months, p=0.01; 
baseline vs. 12 months, p=0.03).
 Safety analysis
Vomiting (15 patients), epigastralgia (10 patients), 
and respiratory infection (9 patients) were the most 
common side effects.
Twenty hospitalisations were registered during 
the study (mean hospitalisation period of 12.5±16.7 
days), none of those considered drug-related.
 DISCUSSION
The results of this study suggest that in regular 
clinical practice cinacalcet consistently reduces iPTH 
levels in patients with SHPT on dialysis. This result 
is observed without increasing Ca, P or CaxP, allow-
ing the percentage of patients achieving the K/DOQI 
recommended targets to increase. Other studies 
have reported similar results in consistently achiev-
ing the K/DOQI recommendations for iPTH, namely 
through comparisons with vitamin D therapy, Ca, P 
and CaxP product6 -9.
According to the literature, iPTH above the maxi-
mum K/DOQI recommended level is associated with 
increased mortality risk11. At baseline, all enrolled 
patients had elevated iPTH levels despite the use of 
vitamin D sterols and phosphate binders, represent-
ing a group of patients that poorly responded to 
conventional therapy. With cinacalcet, the number of 
patients in that situation was rapidly and signifi-
cantly reduced, and this response was sustained 
along the study. In fact, a large percentage of patients 
had iPTH levels <300 pg/ml, after 6 and 12 months 
of cinacalcet administration. This iPTH level has been 
associated with relatively normal bone turnover3,5,19,20 
and is consistent with the K/DOQI guidelines5.
The use of vitamin D analogues, particularly in 
combination with calcium -containing phosphate 
binders, may suppress iPTH concentrations, but can 
often cause hypercalcaemia and hyperphosphatae-
mia by increasing intestinal absorption of calcium 
and phosphorus. These limitations frequently lead 
to undertreatment of the disease, discontinuation of 
therapy, and further progression of SHPT17,18,21.
In our study, the cinacalcet -induced reduction in 
iPTH was accompanied by decreases in serum Ca, 
P, and CaxP levels. After six months of treatment 
with cinacalcet, 69%, 63.6% and 61.8% of the 
patients experienced reduction in Ca, P, and CaxP 
product levels, respectively, demonstrating cinacal-
cet’s ability to control iPTH without increasing serum 
calcium and phosphorus concentrations. These 
results hold particular interest since increases in 
serum phosphorus and CaxP concentrations in 
patients with CKD have been associated with adverse 
cardiovascular outcomes and high mortality 
rates10 -12,22.
Aiming at determining the influence of baseline 
characteristics on treatment outcomes, patients who 
achieved iPTH targets and those who did not were 
compared. Baseline iPTH was significantly higher in 
patients who did not achieve target recommenda-
tions, which leads to the conclusion that disease 
severity is a relevant factor in achieving iPTH target 
levels, highlighting the need to start the treatment 
early. This observation conforms with previous 
reports of larger populations treated with cinacalcet 
during the initial phase III trials8,23. No other differ-
ences were observed in demographics or in clinical 
variables.
The correct control of iPTH levels assumes a major 
importance to avoid two extreme situations; on the 
one hand the risk of undertreatment, and on the 
other the oversuppression of PTH with the conse-
quent development of adynamic bone disease.
Cinacalcet generally had a good safety profile and, 
as reported by other studies, minor gastrointestinal 
symptoms were the most frequent adverse 
events8,9,13,24.
 CONCLUSIONS
Cinacalcet is an effective option for reducing iPTH 
levels with the beneficial effect of decreasing calcium, 
phosphorus and calcium x phosphorus product. The 
incidence of hypercalcaemia or hyperphosphataemia, 
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which currently complicate secondary hyperparathy-
roidism and its conventional management, is 
decreased. Cinacalcet used either with phosphate 
binders alone or in combination with vitamin D ste-
rols and phosphate binders increases the possibility 
of SHPT patients on dialysis achieving and maintain-
ing the K/DOQI treatment targets.
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